📇 Rhumatologue · NANTERRE CEDEX · (92) · Salarié

MME SAHRA ASSIA KERBOUB-KHALFOUN

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Auteur de référence en rhumatologie
27 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
136 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 NANTERRE CEDEX (92)SalariéRPPS 10001632511

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

CH DE NANTERRE
403 AV DE LA REPUBLIQUE, 92014 NANTERRE CEDEX
☎ 0147696565Activité de soin et de pharmacie🏥 Centre CH ↗

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

A Review of the Regulatory Challenges of Personalized Medicine

Cureus · 2024

📚 11 citations🎯 RCR 2.24Top 23% NIH🔓 Open Access📄 PDF gratuit ↗

Colchicine for the treatment of patients with COVID-19: an updated systematic review and meta-analysis of randomised controlled trials

BMJ open · 2024

📚 6 citations🎯 RCR 1.39🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Objectives We conducted an updated systematic review and meta-analysis to investigate the effect of colchicine treatment on clinical outcomes in patients with COVID-19. Design Systematic review and meta-analysis. Data sources We searched PubMed, Embase, the Cochrane Library, medRxiv and ClinicalTrials.gov from inception to January 2023. Eligibility criteria All randomised controlled trials (RCTs) that investigated the efficacy of colchicine treatment in patients with COVID-19 as compared with placebo or standard of care were included. There were no language restrictions. Studies that used colchicine prophylactically were excluded. Data extraction and synthesis We extracted all information relating to the study characteristics, such as author names, location, study population, details of intervention and comparator groups, and our outcomes of interest. We conducted our meta-analysis by using RevMan V.5.4 with risk ratio (RR) and mean difference as the effect measures. Results We included 23 RCTs (28 249 participants) in this systematic review. Colchicine did not decrease the risk of mortality (RR 0.99; 95% CI 0.93 to 1.05; I2=0%; 20 RCTs, 25 824 participants), with the results being consistent among both hospitalised and non-hospitalised patients. There were no significant differences between the colchicine and control groups in other relevant clinical outcomes, including the incidence of mechanical ventilation (RR 0.75; 95% CI 0.48 to 1.18; p=0.22; I2=40%; 8 RCTs, 13 262 participants), intensive care unit admission (RR 0.77; 95% CI 0.49 to 1.22; p=0.27; I2=0%; 6 RCTs, 961 participants) and hospital admission (RR 0.74; 95% CI 0.48 to 1.16; p=0.19; I2=70%; 3 RCTs, 8572 participants). Conclusions The results of this meta-analysis do not support the use of colchicine as a treatment for reducing the risk of mortality or improving other relevant clinical outcomes in patients with COVID-19. However, RCTs investigating early treatment with colchicine (within 5 days of symptom onset or in patients with early-stage disease) are needed to fully elucidate the potential benefits of colchicine in this patient population. PROSPERO registration number CRD42022369850.

Molnupiravir for the treatment of COVID-19 outpatients: An updated meta-analysis

Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2024

📚 4 citations🔓 Open Access

Cookies & analyse de trafic

MME SAHRA ASSIA KERBOUB-KHALFOUN

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (27) — classées par pathologie

Revue générale9

Revue / méta-analyse7

Transversal6

Essai clinique5

Case report / série3

csDMARDs1

Économie santé1

Épidémiologie & registres1

Génétique1

IRM ostéo-articulaire1

Lupus1

Pharmacovigilance1

Tendinopathies & SCC1

Partager cette fiche